Table 1 Clinicopathologic features, treatment and outcome of 751 patients with acute promyelocytic leukaemia in three decades

Sex

 Male

364 (48.5%)

72 (49.3%)

128 (49.8%)

164 (47.1%)

 Female

387 (51.5%)

74 (50.7%)

129 (50.2%)

184 (52.9%)

Presentation leucocyte ^B

 ≤ 10 × 10⁹/L

481 (65.5%)

90 (67.7%)

176 (68.7%)

215 (62.3%)

 > 10 × 10⁹/L

253 (34.5%)

43 (32.3%)

81 (31.3%)

131 (37.7%)

Presentation platelet ^B

 ≤ 40 × 10⁹/L

519 (70.6%)

89 (66.9%)

182 (70.8%)

248 (71.9%)

 > 40 × 10⁹/L

216 (29.4%)

44 (33.1%)

75 (29.2%)

97 (28.1%)

Sanz risk score ^B

 Low

142 (18.9%)

31 (23.3%)

52 (20.2%)

59 (17.1%)

 Intermediate

340 (45.3%)

59 (44.4%)

125 (48.6%)

156 (45.2%)

 High

253 (34.5%)

43 (32.3%)

81 (31.3%)

131 (37.7%)

Induction regimen

 ATRA-based

613 (81.6%)

146 (100%)

254 (98.8%)

213 (61.2%)

 Oral-ATO-based

138 (18.4%)

0

3 (1.2%)^C

138 (38.8%)

CR1 maintenance

 ATRA ± MTX/6-MP

477 (63.5%)

146 (100%)

186 (72.4%)

145 (41.7%)

 Oral-ATO/ATRA based

274 (36.5%)

0

71 (27.6%)

203 (58.3%)

First relapse

97/607 (16%)

26/107(24.3%)

55/203 (27.1%)

16/297(5.4%)

HSCT

 Autologous

13 (1.7%)

6 (4.1%)

5 (1.9%)

2 (0.6%)

 Allogeneic

10 (1.3%)

9 (6.2%)

1 (0.4%)

0

 Second cancers

21 (2.8%)

8 (5.5%)

12 (4.7%)

1 (0.3%)

Deaths

 All causes

271

75 (51.4%)

109 (42.4%)

87 (25%)

 Early deaths

144 (53.1%)

39 (52%)

54 (49.5%)

51 (58.6%)

 Vascular events

7 (2.6%)

0

3 (2.8%)

4 (4.6%)

 Sepsis

18 (6.6%)

3 (4%)

11 (10.1%)

4 (4.6%)

 Second cancers

12 (4.4%)

4 (5.3%)

8 (7.3%)

0

 HSCT-related

7 (2.6%)

7 (9.3%)

0

0

 Refractory leukaemia

49 (18.1%)

19 (25.3%)

26 (23.9%)

4 (4.6%)

 Others

6 (2.2%)

2 (2.7%)

1 (0.9%)

3 (3.4%)

 Not available

28 (10.3%)

1 (1.3%)

6 (5.5%)

21 (24.1%)